SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the first published validation study to evaluate the performance of optical genome mapping (OGM) against traditional cytogenetic techniques for the analysis of hematological neoplasms. According to the study, compared to traditional cytogenetic methods, GMO showed robust technical and analytical performance, corrected misinterpretations, and resolved balanced and unbalanced variants with high resolution in a single assay, streamlining the existing need to run on multiple platforms.
Researchers analyzed samples from 69 people referred to a clinical laboratory for cytogenetic analysis to assess GMO as an approach to providing cytogenetic profiling in hematological neoplasms which included acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). GMO’s technical performance resulted in a 100% first pass rate, with agreement with traditional methods showing 98.7% sensitivity, 100% specificity and 99.2% accuracy. GMO has identified several additional structural variants (SVs) not detected by other methods, revealing the genomic architecture of these neoplasms which the study authors believe could provide an opportunity for better classification of tumors, a prognosis, risk stratification and therapy selection.
Erik Holmlin, PhD, President and CEO of Bionano commented, “We are excited to see the study results showing how GMO can be useful in the analysis of hematological neoplasms. We believe the study results show that GMO can alleviate the need for several technologies and has the potential to become a first-level cytogenomic test for hematological malignancies.
This publication can be found here: https://www.jmdjournal.org/article/S1525-1578(22)00290-2/fulltext
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to find answers to complex questions in biology and medicine. The company’s mission is to transform the way the world views the genome through GMO solutions, diagnostic services and software. The company offers GMO solutions for applications in basic, translational and clinical research. Through its business Lineagen, Inc. d/b/a Bionano Laboratories, the company also provides diagnostic tests for patients with clinical presentations consistent with autism spectrum disorders and other neurodevelopmental disorders. Through its BioDiscovery business, the company also offers a leading-edge, platform-independent software solution that integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and a report of copy number variants, single nucleotide variants and absence of heterozygosity across the genome in a consolidated view. For more information, visit www.bionanogenomics.com, www.bionanolaboratories.com Where www.biodiscovery.com
Bionano Genomics Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe”, “potential”, “may”, “believe” and similar expressions (as well as other words or phrases that refer to future events, conditions or circumstances) convey uncertainty about future events or results and are intended to identify such forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyzes or current expectations regarding, among other things, the usefulness of GMOs in providing cytogenetic profiling in hematological neoplasms which included acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied by such forward-looking statements. Factors that could cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or enhancements to existing technologies; the failure of GMOs to be adopted as a tool for cytogenetic profiling in hematological neoplasms this included acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL); results of future studies contradicting the results reported in the publication referenced above; changes in our strategic and business plans; our ability to obtain sufficient financing to fund our strategic plans and marketing efforts; the ability of medical and research institutions to obtain funding to support the adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition generally, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on form 10-K for the year ended December 31, 2021 and in other filings subsequently filed by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date they were made and are based on management’s assumptions and estimates as of that date. We undertake no obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
tip of the juniper
+1 (858) 366-3243